Department of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan, Kazakhstan.
Laboratory of Stem Cells, National Center for Biotechnology, Nur-Sultan, Kazakhstan.
Front Immunol. 2022 Sep 23;13:1010399. doi: 10.3389/fimmu.2022.1010399. eCollection 2022.
Considering the unique therapeutic potential of mesenchymal stem cells (MSCs), including their immunosuppressive and immunomodulatory properties as well as their ability to improve tissue regeneration, these cells have attracted the attention of scientists and clinicians for the treatment of different inflammatory and immune system mediated disorders. However, various clinical trials using MSCs for the therapeutic purpose are conflicting and differ from the results of promising preclinical studies. This inconsistency is caused by several factors such as poor migration and homing capacities, low survival rate, low level of proliferation and differentiation, and donor-dependent variation of the cells. Enhancement and retention of persistent therapeutic effects of the cells remain a challenge to overcome in MSC-based therapy. In this review, we summarized various approaches to enhance the clinical outcomes of MSC-based therapy as well as revised current and future perspectives for the creation of cellular products with improved potential for diverse clinical applications.
考虑到间充质干细胞（MSCs）的独特治疗潜力，包括其免疫抑制和免疫调节特性以及改善组织再生的能力，这些细胞引起了科学家和临床医生的关注，可用于治疗不同的炎症和免疫系统介导的疾病。然而，使用 MSCs 进行治疗的各种临床试验存在冲突，与有前景的临床前研究结果不同。这种不一致性是由多种因素引起的，例如迁移和归巢能力差、存活率低、增殖和分化水平低以及供体依赖性细胞变异。增强和保持细胞的持久治疗效果仍然是 MSC 治疗中需要克服的挑战。在这篇综述中，我们总结了各种方法来增强基于 MSC 的治疗的临床效果，并修订了当前和未来的观点，以创造具有改善的多样化临床应用潜力的细胞产品。
